Literature DB >> 2582443

Expression and precursor processing of neuropeptide Y in human and murine neuroblastoma and pheochromocytoma cell lines.

M M O'Hare1, T W Schwartz.   

Abstract

The synthesis and processing of the precursor for neuropeptide Y (NPY) were studied in 16 human and murine neuroendocrine cell lines. Eight of the cell lines, NS-20Y, PC12, LA-N-5, CHP-234, SMS-KCNR, SH-SY5Y, SMS-KCN, and BE(2)-M17, produced sufficient quantities to permit chromatographic characterization of the NPY immunoreactivity. Although the cell lines varied in the amount of NPY they produced, both within and between cell lines, they displayed a relatively constant pattern of posttranslational modifications. In contrast to observations in tumor extracts (M. M. T. O'Hare and T. W. Schwartz, Cancer Res., 49: 7010-7014, 1989), all cell lines studied contained a substantial amount of the intracellular NPY in the form of the unprocessed propeptide, 57% (range, 33-72%) as characterized by both gel filtrations (32 experiments in 8 cell lines) and "in vitro conversion" with endoproteinase Lys-C. In the majority, 4 of 6 cell lines studied, almost all of the NPY, which by size corresponded to the mature 36-amino acid form, was amidated as assessed by isoelectric focusing and by a radioimmunoassay specific for the COOH-terminal amide group of the peptide. Both the propeptide and smaller molecular forms of NPY were secreted from the cell cultures; however, proteolytic degradation in the tissue culture medium prevented a detailed, meaningful characterization of these peptides. It is concluded that many neuroendocrine cell lines, especially those derived from human neuroblastomas, express the NPY gene; the cells display a partly impaired dibasic processing capacity but they generally amidate the products efficiently.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2582443

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Expression and processing of procholecystokinin in a rat medullary thyroid carcinoma cell line.

Authors:  L Odum; J F Rehfeld
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

2.  Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

Authors:  C Lu; L Everhart; J Tilan; L Kuo; C-C J Sun; R B Munivenkatappa; A-C Jönsson-Rylander; J Sun; A Kuan-Celarier; L Li; K Abe; Z Zukowska; J A Toretsky; J Kitlinska
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

3.  Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1.

Authors:  Anna Sandebring; Kelly Jean Thomas; Alexandra Beilina; Marcel van der Brug; Megan M Cleland; Rili Ahmad; David W Miller; Ibardo Zambrano; Richard F Cowburn; Homira Behbahani; Angel Cedazo-Mínguez; Mark R Cookson
Journal:  PLoS One       Date:  2009-05-27       Impact factor: 3.240

4.  Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours.

Authors:  P Bjellerup; E Theodorsson; H Jörnvall; P Kogner
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

5.  Neuronal conditioning medium and nerve growth factor induce neuronal differentiation of collagen-adherent progenitors derived from human umbilical cord blood.

Authors:  Hadar Arien-Zakay; Arnon Nagler; Hanan Galski; Philip Lazarovici
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.